RT Journal Article
T1 Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study.
A1 Schettini, Francesco
A1 Sobhani, Navid
A1 Ianza, Anna
A1 Triulzi, Tiziana
A1 Molteni, Alfredo
A1 Lazzari, Maria Chiara
A1 Strina, Carla
A1 Milani, Manuela
A1 Corona, Silvia Paola
A1 Sirico, Marianna
A1 Bernocchi, Ottavia
A1 Giudici, Fabiola
A1 Cappelletti, Maria Rosaria
A1 Ciruelos, Eva
A1 Jerusalem, Guy
A1 Loi, Sherine
A1 Fox, Stephen B
A1 Generali, Daniele
K1 Biomarker
K1 Breast cancer
K1 Everolimus
K1 Hormone receptors
K1 Immunomodulation
K1 mTOR
AB mTOR inhibitor everolimus is used for hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC). No reliable predictive biomarker of response is available. Following evidences from other solid tumors, we aimed to assess the association between treatment-associated immune system features and everolimus activity. We retrospectively explored a correlation with the therapeutic activity of everolimus and tumor-associated immune pathways with ingenuity pathway analysis (IPA), neutrophil-to-lymphocyte ratio (NLR), circulating lymphocytes, and endothelial cells (CECs) in 3 different HR+ mBC studies, including the BALLET phase IIIb study. The circulating levels of CD3+/CD8+, CD3+/CD4+, and overall T lymphocytes were higher in responders versus non-responders at baseline (p = 0.017, p  4.4) (p = 0.01). IPA showed that the majority of immunity-related genes were found upregulated in responders compared to non-responders before treatment, but not after. Lymphocytes subpopulations, CECs and NLR could be interesting biomarkers predictive of response to everolimus-based regimens, potentially useful in daily clinical practice to select/monitor everolimus-based treatment in mBC. Further studies to confirm such hypotheses are warranted.
YR 2020
FD 2020-08-07
LK https://hdl.handle.net/10668/25332
UL https://hdl.handle.net/10668/25332
LA en
DS RISalud
RD Apr 12, 2025